219 related articles for article (PubMed ID: 1692981)
21. Laboratory studies for the detection of carcinoma of the prostate.
Brawer MK
Urol Clin North Am; 1990 Nov; 17(4):759-68. PubMed ID: 1699341
[TBL] [Abstract][Full Text] [Related]
22. Tumor markers. Consensus Conference on Diagnosis and Prognostic Parameters in Localized Prostate Cancer. Stockholm, Sweden, May 12-13, 1993.
Stamey TA; Ekman PE; Blankenstein MA; Cooper EH; Kontturi M; Lilja H; Oesterling JE; Stenman UH; Turkes A
Scand J Urol Nephrol Suppl; 1994; 162():73-87; discussion 115-27. PubMed ID: 7529430
[TBL] [Abstract][Full Text] [Related]
23. Assessment of response to carboplatin in patients with hormone-refractory prostate cancer: a critical analysis of drug activity.
Miglietta L; Cannobbio L; Boccardo F
Anticancer Res; 1995; 15(6B):2825-8. PubMed ID: 8669872
[TBL] [Abstract][Full Text] [Related]
24. [New prospective diagnostic serum markers in prostatic cancer].
Mirone V; De Bellis G; Prezioso D; Sanseverino R; Iannucci F; Padulano P
Minerva Med; 1986 Mar; 77(13):503-4. PubMed ID: 2422605
[No Abstract] [Full Text] [Related]
25. Prostate carcinoma staging. Clinical utility of bone alkaline phosphatase in addition to prostate specific antigen.
Morote J; Lorente JA; Encabo G
Cancer; 1996 Dec; 78(11):2374-8. PubMed ID: 8941009
[TBL] [Abstract][Full Text] [Related]
26. [PSA in the staging and monitoring of cancer of the prostate].
Gil Sanz MJ; Sanz Velez JI; Liedana Torres JM; Roncales Badal AL; Allepuz Losa C; Rioja Sanz LA
Actas Urol Esp; 1991; 15(6):527-31. PubMed ID: 1724347
[TBL] [Abstract][Full Text] [Related]
27. [Clinical study of tumor markers in prostatic cancer].
Ishihara Y; Fukagai T; Ohta K; Hiromoto Y; Hiramori M; Torii T; Higaki Y; Imamura K
Hinyokika Kiyo; 1990 Apr; 36(4):425-31. PubMed ID: 1696063
[TBL] [Abstract][Full Text] [Related]
28. [Prostatic diseases: tumor markers (PAP and PSA) and age at risk].
Manna A; Trasatti L; Cifaldi L; Marchei GG; Reale MG; Marchei P
J Nucl Med Allied Sci; 1990; 34(4 Suppl):91. PubMed ID: 1709213
[No Abstract] [Full Text] [Related]
29. [Can the tumor stage of prostate carcinoma be determined with the aid of prostate-specific antigen?].
Semjonow A; Hertle L
Urologe A; 1995 Jul; 34(4):290-6. PubMed ID: 7545843
[TBL] [Abstract][Full Text] [Related]
30. [Recrudescence of prostate cancer with low serum level of PSA and high serum level of CEA and CA19-9: a case report].
Yokoyama S; Fukuhara S; Imazu T; Hara T; Yamaguchi S; Adachi S
Hinyokika Kiyo; 2007 Jul; 53(7):485-7. PubMed ID: 17702183
[TBL] [Abstract][Full Text] [Related]
31. [Analysis of the serum concentration of prostate-specific antigen as a biological marker in the evolution of disseminated prostatic cancer].
Morote Robles J; de Torres Mateos JA; Soler-Roselló A
Actas Urol Esp; 1988; 12(2):152-7. PubMed ID: 2458015
[No Abstract] [Full Text] [Related]
32. [Prostate-specific antigen. A new marker of prostatic pathology].
Boccon-Gibod L; Géraud M; Dugué MA
Ann Urol (Paris); 1988; 22(3):206-10. PubMed ID: 2456714
[TBL] [Abstract][Full Text] [Related]
33. Prostate cancer-associated markers.
Chu TM
Immunol Ser; 1990; 53():339-56. PubMed ID: 1713065
[TBL] [Abstract][Full Text] [Related]
34. Markers of undiagnosed incidental cancer in comparison with clinical prostatic cancer.
Ogawa A; Yoshida A; Kanda T; Sugihara S; Suzuki T; Tamura J; Kobayashi I; Nakazato Y
J Med; 2000; 31(1-2):101-10. PubMed ID: 10998759
[TBL] [Abstract][Full Text] [Related]
35. The present role of prostatic specific antigen (PSA) as a tumor marker in carcinoma of the prostate.
Parra RO
Mo Med; 1991 Jun; 88(6):349-52. PubMed ID: 1712422
[TBL] [Abstract][Full Text] [Related]
36. [Prostate-specific antigen. A new biological serum marker for prostatic adenocarcinoma].
Haukaas S; Skaarland E; Halvorsen OJ; Stensland E; Farstad M
Tidsskr Nor Laegeforen; 1990 Sep; 110(23):2990-3. PubMed ID: 1700496
[TBL] [Abstract][Full Text] [Related]
37. [The value of prostate-specific antigen in therapy follow-up of prostatic carcinoma].
Wirth MP; Pilarsky C
Urologe A; 1995 Jul; 34(4):297-302. PubMed ID: 7545844
[TBL] [Abstract][Full Text] [Related]
38. Correlation of cell proliferation marker (TPS), natural killer (NK) activity and tumor load serotest (PSA) in untreated and treated prostatic tumors.
Tarle M; Kovacić K; Kastelan M
Anticancer Res; 1993; 13(1):215-8. PubMed ID: 7682800
[TBL] [Abstract][Full Text] [Related]
39. [Occult cancer in patients with symptomatic benign prostatic hyperplasia].
Rodríguez Duarte C; Aguillón J; Rodríguez H
Arch Esp Urol; 1991 May; 44(4):411-4. PubMed ID: 1712190
[TBL] [Abstract][Full Text] [Related]
40. [Prostate-specific antigen (PSA): diagnostic and prognostic implications in the evaluation of carcinoma of the prostate].
Lo Cigno M; Montanari F; Bercovich E; Soli M; Emili E; Dal Pozzo C; Platè L; Bianchi D
Arch Ital Urol Nefrol Androl; 1989 Mar; 61(1):29-36. PubMed ID: 2469127
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
